BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38675657)

  • 21. Coordination-driven FBXW7 DNAzyme-Fe nanoassembly enables a binary switch of breast cancer cell cycle checkpoint responses for enhanced ferroptosis-radiotherapy.
    Yu J; Zhang Y; Li L; Xiang Y; Yao X; Zhao Y; Cai K; Li M; Li Z; Luo Z
    Acta Biomater; 2023 Oct; 169():434-450. PubMed ID: 37516418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Separation and identification of tubocapsanolide MAP and tubocapsunolide A, and the structure-activity relationship of their anti-TNBC activity.
    Shou P; Li J; Wei Y; Kai G; Wang F; Zhao H; Yang B
    Steroids; 2020 Dec; 164():108734. PubMed ID: 33010265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53/SLC7A11 axis.
    Ma S; Ma Y; Qi F; Lei J; Chen F; Sun W; Wang D; Zhou S; Liu Z; Lu Z; Zhang D
    World J Surg Oncol; 2023 Sep; 21(1):293. PubMed ID: 37718459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
    Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
    J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway.
    Yu X; He Z; Wang Z; Ke S; Wang H; Wang Q; Li S
    Exp Cell Res; 2024 May; 438(2):114053. PubMed ID: 38663476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexamethasone induces ferroptosis via P53/SLC7A11/GPX4 pathway in glucocorticoid-induced osteonecrosis of the femoral head.
    Sun F; Zhou JL; Liu ZL; Jiang ZW; Peng H
    Biochem Biophys Res Commun; 2022 Apr; 602():149-155. PubMed ID: 35276555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WTAP Mediates NUPR1 Regulation of LCN2 Through m
    Tan M; He Y; Yi J; Chen J; Guo Q; Liao N; Peng L
    Biochem Genet; 2024 Apr; 62(2):876-891. PubMed ID: 37477758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species.
    Roy A; Ahir M; Bhattacharya S; Parida PK; Adhikary A; Jana K; Ray M
    Mol Carcinog; 2017 Sep; 56(9):2086-2103. PubMed ID: 28418078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Danggui Buxue Tang improves therapeutic efficacy of doxorubicin in triple negative breast cancer via ferroptosis.
    Gong G; Ganesan K; Liu Y; Huang Y; Luo Y; Wang X; Zhang Z; Zheng Y
    J Ethnopharmacol; 2024 Apr; 323():117655. PubMed ID: 38158099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
    Wang F; Yang Y
    Breast Cancer Res Treat; 2014 Aug; 147(1):203-10. PubMed ID: 25085754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.
    Wang HC; Hu HH; Chang FR; Tsai JY; Kuo CY; Wu YC; Wu CC
    Phytomedicine; 2019 Feb; 53():213-222. PubMed ID: 30668401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Icariin inhibits chondrocyte ferroptosis and alleviates osteoarthritis by enhancing the SLC7A11/GPX4 signaling.
    Xiao J; Luo C; Li A; Cai F; Wang Y; Pan X; Xu L; Wang Z; Xing Z; Yu L; Chen Y; Tian M
    Int Immunopharmacol; 2024 May; 133():112010. PubMed ID: 38636375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rubioncolin C, a natural naphthohydroquinone dimer isolated from Rubia yunnanensis, inhibits the proliferation and metastasis by inducing ROS-mediated apoptotic and autophagic cell death in triple-negative breast cancer cells.
    Li L; Wang J; Feng L; Fan J; Wang J; Tan N; Wang Z
    J Ethnopharmacol; 2021 Sep; 277():114184. PubMed ID: 33961996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses.
    Jiang L; Hickman JH; Wang SJ; Gu W
    Cell Cycle; 2015; 14(18):2881-5. PubMed ID: 26218928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yttrium Oxide nanoparticles induce cytotoxicity, genotoxicity, apoptosis, and ferroptosis in the human triple-negative breast cancer MDA-MB-231 cells.
    Emad B; WalyEldeen AA; Hassan H; Sharaky M; Abdelhamid IA; Ibrahim SA; Mohamed HR
    BMC Cancer; 2023 Nov; 23(1):1151. PubMed ID: 38012585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Jing-Fang n-butanol extract and its isolated JFNE-C inhibit ferroptosis and inflammation in LPS induced RAW264.7 macrophages via STAT3/p53/SLC7A11 signaling pathway.
    Li X; Qi H; Zhang X; Liang H; Zeng N
    J Ethnopharmacol; 2023 Nov; 316():116689. PubMed ID: 37315642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
    Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.